A follow-up to this study, the ATPAHSS-O trial (SSc-PAH), showed improvement in both RV and LV function as assessed by CMR, as well as improvement in 6MW distance, pro-BNP, and hemodynamics [98]. The gene discussed is NPPB; the disease is pulmonary arterial hypertension.